Selective adenosine agonists and myocardial perfusion imaging

Journal of Nuclear Cardiology

Volumn 19, Issue 1, 2012, Pages 126-141

  Zoghbi, Gilbert J ^a,b   Iskandrian, Ami E ^a  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Apadenoson; Binodenoson; Myocardial perfusion imaging; Regadenoson; Selective adenosine agonists

Indexed keywords

ADENOSINE; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; AMINOPHYLLINE; APADENOSON; ATL 149E; BINODENOSON; CORVUE; INSULIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PLACEBO; REGADENOSON; THALLIUM 201; UNCLASSIFIED DRUG; WATER O 15; ADENOSINE RECEPTOR STIMULATING AGENT; DIAGNOSTIC AGENT; VASODILATOR AGENT;

ABDOMINAL DISCOMFORT; ANGINA PECTORIS; ATRIOVENTRICULAR BLOCK; BLOOD FLOW VELOCITY; BRONCHOSPASM; COMPLETE HEART BLOCK; CONTINUOUS INFUSION; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY VASCULAR RESISTANCE; DEATH; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISTRIBUTION VOLUME; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DYSPNEA; EXERCISE TEST; FLUSHING; HEART HEMODYNAMICS; HEART INFARCTION; HEART MUSCLE BLOOD FLOW; HEART RATE; HEAT SENSATION; HUMAN; HYPEREMIA; HYPOTENSION; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MAXIMUM PLASMA CONCENTRATION; MYOCARDIAL PERFUSION IMAGING; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGIC STRESS TESTING; PLASMA CONCENTRATION-TIME CURVE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; VASODILATATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; IMAGE ENHANCEMENT; METHODOLOGY;

EXERCISE TEST; HUMANS; IMAGE ENHANCEMENT; MYOCARDIAL PERFUSION IMAGING; PURINERGIC P1 RECEPTOR AGONISTS; TOMOGRAPHY, EMISSION-COMPUTED; VASODILATOR AGENTS;

EID: 84861509861     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-011-9474-9     Document Type: Review

References (41)

1. Orlandi C. Pharmacology of coronary vasodilation: A brief review. J Nucl Cardiol 1996;3:S27-30.
2. Kaul S. The role of capillaries in determining coronary blood flow reserve: Implications for stress-induced reversible perfusion defects. J Nucl Cardiol 2001;8:694-700. (Pubitemid 33150248)
3. Wacker CM, Bauer WR. Myocardial microcirculation in humans - new approaches using MRI. Herz 2003;28:74-81. (Pubitemid 36406361)
4. Zoghbi GJ, Iskandrian AE. Pharmacological stress testing. In: Garcia EV, Iskandrian AE, editors. Nuclear cardiac imaging: Principles and applications. New York: Oxford University Press; 2008. p. 293-315.
5. Gemignani AS, Abbott BG. The emerging role of the selective A2A agonist in pharmacologic stress testing. J Nucl Cardiol 2010; 17:494-7.
6. Olah ME, Stiles GL. Adenosine receptor subtypes: Characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 1995;35:581-606.
7. Hendel RC, Jamil T, Glover DK. Pharmacologic stress testing: New methods and new agents. J Nucl Cardiol 2003;10:197-204. (Pubitemid 36503806)
8. Sato A, Terata K, Miura H, Toyama K, Loberiza FR Jr, Hatoum OA, et al. Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease. Am J Physiol Heart Circ Physiol 2005;288:H1633-40. (Pubitemid 40417986)
9. Muller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta 2010;1808:1290-308.
10. Al Jaroudi W, Iskandrian AE. Regadenoson: A new myocardial stress agent. J Am Coll Cardiol 2009;54:1123-30.
11. Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 2007;14:514-20. (Pubitemid 47163555)
12. Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 2006;45:1201-12. (Pubitemid 44904823)
13. Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 2007;47:825-33.
14. Barrett RJ, Lamson MJ, Johnson J, Smith WB. Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers. J Nucl Cardiol 2005;12:166-71. (Pubitemid 40450766)
15. Glover DK, Ruiz M, Takehana K, Petruzella FD, Riou LM, Rieger JM, et al. Pharmacological stress myocardial perfusion imaging with the potent and selective A(2A) adenosine receptor agonists ATL193 and ATL146e administered by either intravenous infusion or bolus injection. Circulation 2001;104:1181-7. (Pubitemid 32830405)
16. Gao Z, Li Z, Baker SP, Lasley RD, Meyer S, Elzein E, et al. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: Inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther 2001;298:209-18. (Pubitemid 32574529)
17. Cerqueira MD. The future of pharmacologic stress: Selective A2A adenosine receptor agonists. Am J Cardiol 2004;94:33D-40D. discussion 40D-42D.
18. Trochu JN, Zhao G, Post H, Xu X, Belardinelli L, Belloni FL, et al. Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: Potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol 2003;41:132-9. (Pubitemid 36015065)
19. Zhao G, Linke A, Xu X, Ochoa M, Belloni F, Belardinelli L, et al. Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs. J Pharmacol Exp Ther 2003;307:182-9. (Pubitemid 37151905)
20. Mekkaoui C, Jadbabaie F, Dione DP, Meoli DF, Purushothaman K, Belardinelli L, et al. Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics. JACC Cardiovasc Imaging 2009;2:1198-208.
21. GloverDK,RuizM,Yang JY,KoplanBA,AllenTR, SmithWH, et al. Pharmacological stress thallium scintigraphy with 2-cyclohexylmethylidenehydrazinoadenosine (WRC-0470). A novel, shortacting adenosineA2Areceptor agonist. Circulation 1996;94:1726-32. (Pubitemid 26320281)
22. Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther 2006;316:695-702. (Pubitemid 43130996)
23. Zhao G, Serpllion S, Shryock J, Messina E, Xu X, Ochoa M, et al. Regadenoson, a novel pharmacologic stress agent for use in myocardial perfusion imaging, does not have a direct effect on the QT interval in conscious dogs. J Cardiovasc Pharmacol 2008;52:467-73.
24. Zhao G, Messina E, Xu X, Ochoa M, Sun HL, Leung K, et al. Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist. J Cardiovasc Pharmacol 2007;49:369-75. (Pubitemid 47000311)
25. Hodgson JM, Dib N, Kern MJ, Bach RG, Barrett RJ. Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol 2007;99:1507-12. (Pubitemid 46770630)
26. Kern MJ, Hodgson JM, Dib N, Mittleman RS, Crane PD. Effects of apadenoson, a selective adenosine A2a receptor agonis for myocardial perfusion imaging, on coronary blood flow velocity in conscious patients. Circulation 2006;114:582. (Abstract).
27. Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B, et al. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 2005;46:2069-75. (Pubitemid 41713594)
28. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58. (Pubitemid 47355078)
29. Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, et al. Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J 2009;157:771-6.
30. Hage FG, Perry G, Heo J, Iskandrian AE. Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome. Am J Cardiol 2010;105:839-43.
31. Udelson JE, Heller GV, Wackers FJ, Chai A, Hinchman D, Coleman PS, et al. Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging. Circulation 2004;109:457-64. (Pubitemid 38168506)
32. Gaemperli O, Schepis T, Koepfli P, Siegrist PT, Fleischman S, Nguyen P, et al. Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: A randomized, double-blind, placebo-controlled crossover trial. J Am Coll Cardiol 2008;51:328-9.
33. Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: A quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging 2009;2:959-68.
34. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008;1:307-16. (Pubitemid 351676842)
35. Leaker BR, O'Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebocontrolled trial. J Nucl Cardiol 2008;15:329-36.
36. Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008;15:319-28.
37. Murray JJ, Weiler JM, Schwartz LB, Busse WW, Katial RK, Lockey RF, et al. Safety of binodenoson, a selective adenosine A2A receptor agonist vasodilator pharmacological stress agent, in healthy subjects with mild intermittent asthma. Circ Cardiovasc Imaging 2009;2:492-8.
38. Aljaroudi W, Hermann D, Hage F, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage renal disease. Am J Cardiol 2009;105:133-5.
39. Aljaroudi W, Iqbal F, Koneru J, Bhambhvani P, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage liver disease. J Nucl Cardiol 2011;18:90-5.
40. Thomas GS, Thompson RC, Miyamoto MI, Ip TK, Rice DL, Milikien D, et al. The RegEx trial: A randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009;16:63-72.
41. Kwon DH, Cerqueira MD, Young R, Houghtaling P, Lieber E, Menon V, et al. Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: Initial clinical experience in 1263 patients. J Nucl Cardiol 2010;17:853-7.